Clinical Trial Update: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma [Phase 1]

View source ↗

Summary

This Phase I/Ib trial assesses safety and early efficacy signals for nivolumab plus veliparib in patients with advanced solid tumors and aggressive non-Hodgkin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Solid Tumors
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• OPDIVO (nivolumab)
• Veliparib (veliparib)

Snippet

Sponsor: Northwestern University | Conditions: Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-11-19